RIL's genomic test co Strand looks at tier-II, -III markets

Genomic testing has been rising in diagnosis, mainly among tertiary specialists in metros and tier-I cities

- Jessica Jani

The genomic testing market in India, still nascent, is poised for big growth in the coming years as demand increases on the back of changing disease patterns, more awareness, and falling prices.

Companies such as Strand Life Sciences, a subsidiary of Reliance Industries Ltd, and MedGenome are increasing their footprint via organic and inorganic routes, with a focus on the smaller cities and towns.